Transverse Myelitis Market to Witness Robust Growth Due to Rising Awareness About Rare Diseases
The increasing prevalence of rare autoimmune neurological disorders and growing awareness regarding their diagnosis and treatment are fueling the growth of the transverse myelitis market. Transverse myelitis (TM) is a rare neurological disorder characterized by inflammation of the spinal cord which often damages its protective covering called myelin sheath. If left untreated, it can cause weakness, sensory alterations or autonomic nervous system dysfunction.
The Global Transverse Myelitis Market is estimated to be valued at USD 710.1 Mn in 2024 and is expected to reach USD 967.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.23% from 2024 to 2031.
Key players operating in the transverse myelitis market are GlaxoSmithKline, Teva Pharmaceuticals, Pfizer, Novartis, Mylan, Baxter, and Johnson & Johnson.
Key Takeaways
Key players: Key players operating in the transverse myelitis market are GlaxoSmithKline, Teva Pharmaceuticals, Pfizer, Novartis, Mylan, Baxter, and Johnson & Johnson. GlaxoSmithKline is one of the leading players in transverse myelitis treatment market with drugs like Aubagio and Copaxone used for relapsing-remitting multiple sclerosis which is a primary cause of transverse myelitis.
Key opportunities: Rising investments by biopharma players in R&D of novel drugs and supportive government initiatives to promote orphan drug development present significant growth opportunities in the Transverse Myelitis Market.
Global expansion: The transverse myelitis treatment market is expected to witness fastest growth in Asia Pacific and Latin America regions due to increase in healthcare expenditures, healthcare reforms and expansion efforts of top players.
Market drivers: Increasing awareness about rare neurological diseases and their symptoms through social media and patient advocacy groups is a major market driver. Growing patient referrals to neurologists and availability of diagnostic tools is also propelling the demand for transverse myelitis treatment worldwide.
PEST Analysis
Political: Regulations related to healthcare, drugs and medical devices. Government policies regarding reimbursement and healthcare coverage.
Economic: Economic growth, unemployment rates, interest rates affect healthcare spending ability of consumers. Rising per capita incomes increase affordability of advanced treatments.
Social: Changing lifestyle, increasing health awareness drives demand for advanced diagnostic and treatment options. Aging population is vulnerable to neurological conditions.
Technological: Advancements in areas of stem cell therapies, biomarkers, neuroimaging techniques have improved diagnostics and made customized treatment strategies possible. Wearable sensor technology and e-health platforms facilitate remote monitoring.
Market Concentration
The market in terms of value is largely concentrated in developed regions like North America and Western Europe. This is owing to advanced healthcare infrastructure, high per capita healthcare expenditure, and well established healthcare reimbursement systems in these regions which make advanced therapies easily accessible.
Fastest Growing Region
The Asia Pacific region is projected to witness the highest growth in the transverse myelitis market during the forecast period. This isdue to improving healthcare standards, increasing investments by market players, growing medical tourism industry and rising disease prevalence in developing country markets like India and China. Growing awareness about neurological disorders and expanding insured population base are some key factors propelling regional market growth.
Get more insights on: Transverse Myelitis Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)